Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumor

NCT05253053 is registered in ClinicalTrials.gov with TransThera Sciences (Nanjing), Inc. as lead sponsor.

NCT NCT05253053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05253053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumor
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
April 13, 2022
Completion date
August 31, 2024
Enrollment
84 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, biliary tract cancer, bladder cancer, cholangiocarcinoma, gallbladder cancer, gastric cancer, her2-negative breast cancer, prostate cancer, small-cell lung cancer, thyroid cancer, triple negative breast cancer